TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.
Brief Summary: Purpose: The purpose of this study is to investigate the efficacy of Dialectical Behavior Therapy (DBT) versus CAMS (Collaborative Assessment and Management of Suicidality) -informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self behavior and personality traits within the spectrum of borderline personality disorder.

Hypothesis: The hypothesis is 16 weeks of treatment with Dialectical Behavior Therapy (DBT) after a defined manual has a higher efficacy than CAMS-informed supportive psychotherapy on self-harm acts, suicide attempts, suicidal ideation, depressive symptoms, impulsiveness and consumption of hospital services in patients with symptoms within the spectrum of borderline personality disorder (BDP).

Method: The investigators will include 160 patients in the randomized trial to investigate whether 16 weeks of DBT-treatment as a higher efficacy than CAMS-informed supportive psychotherapy on the risk of self-harm acts and suicide attempts in patients with self-harm behavior and personality traits within the spectrum of borderline personality disorder. The trial will meet strict criteria for high quality randomized trials, and will hopefully help to establish evidence for the treatment of this patient group at higher risk of later suicide. There will be performed follow up interviews after 16 weeks, 28 weeks and 52 weeks.


Options:
A: Arm Label: Intervention Group ASSIP; Type: EXPERIMENTAL; Interventions: Behavioral: Attempted Suicide Short Intervention Program (ASSIP) | Arm Label: Control Group CG; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group (CG) | Intervention Type: BEHAVIORAL; Name: Attempted Suicide Short Intervention Program (ASSIP); Assigned to Arm(s): Intervention Group ASSIP | Intervention Type: BEHAVIORAL; Name: Control Group (CG); Assigned to Arm(s): Control Group CG
B: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: OPAC (Outreach, Problem solving, Adherence, Continuity) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: OPAC (Outreach, Problem solving, Adherence, Continuity); Assigned to Arm(s): 1
D: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Determine Outcome and Cost Effectiveness of Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease (COPD) in a Danish Setting
Brief Summary: This randomized controlled trial (RCT) will examine a nurse case management model for patients suffering from chronic obstructive pulmonary disease (COPD) in a Danish municipality, and is performed in order to evaluate the use of case management as a tool in achieving integrated, quality and cost-effective care for this group of patients.

The main objectives are to evaluate how case management influences on hospital admissions, mortality, quality of life and self care, as well as to compare costs and cost-effectiveness of case management vs. usual care.


Options:
A: Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Case Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management
B: Arm Label: Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health Coaching | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health Coaching; Assigned to Arm(s): Health Coaching
C: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
D: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Determine Outcome and Cost Effectiveness of Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease (COPD) in a Danish Setting
Brief Summary: This randomized controlled trial (RCT) will examine a nurse case management model for patients suffering from chronic obstructive pulmonary disease (COPD) in a Danish municipality, and is performed in order to evaluate the use of case management as a tool in achieving integrated, quality and cost-effective care for this group of patients.

The main objectives are to evaluate how case management influences on hospital admissions, mortality, quality of life and self care, as well as to compare costs and cost-effectiveness of case management vs. usual care.


Options:
A: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)
B: Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Case Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management
C: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home, Behavioral: Telemonitoring and education/self-management | Arm Label: Unsupervised exercise training at home; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training at home; Assigned to Arm(s): Telerehabilitation, Unsupervised exercise training at home | Intervention Type: BEHAVIORAL; Name: Telemonitoring and education/self-management; Assigned to Arm(s): Telerehabilitation
D: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Internet-mediated Walking Program; Type: OTHER; Interventions: Behavioral: automated internet-mediated walking program | Intervention Type: BEHAVIORAL; Name: automated internet-mediated walking program; Assigned to Arm(s): Internet-mediated Walking Program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14 Day, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose, Phase III Clinical Trial to Assess the Efficacy and Safety of TRK-820 in Treating Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
Brief Summary: The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.


Options:
A: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): montelukast | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: TRK-820 5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: nalfurafine hydrochloride (TRK-820) | Arm Label: TRK-820 2.5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: nalfurafine hydrochloride (TRK-820) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: nalfurafine hydrochloride (TRK-820); Assigned to Arm(s): TRK-820 2.5μg, TRK-820 5μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ergocalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50,000 Units Ergocalciferol | Arm Label: oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 50,000 Units Ergocalciferol; Assigned to Arm(s): Ergocalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): oral placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 2.5 µg | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 5.0 µg | Intervention Type: DRUG; Name: Nalfurafine HCl 2.5 µg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Nalfurafine HCl 5.0 µg; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rationalisation of Polypharmacy in the Elderly by the RASP Instrument (Rationalisation of Home Medication by an Adjusted STOPP-list in Older Patients): a Prospective, Clinical Trial.
Brief Summary: The aim of this study is to determine whether a clinical pharmacist using the RASP list (RASP = Rationalisation of home medication by an adjusted STOPP-list in older patients; STOPP = Screening Tool of Older Persons' potentially inappropriate Prescriptions) can optimise the drug use in elderly inpatients.


Options:
A: Arm Label: RASP; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmaceutical care plan, mostly based on the RASP | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care plan, mostly based on the RASP; Assigned to Arm(s): RASP
B: Arm Label: Exercise with Whole-body vibration platform; Type: EXPERIMENTAL; Interventions: Device: Exercise with Whole-body vibration platform | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: DEVICE; Name: Exercise with Whole-body vibration platform; Assigned to Arm(s): Exercise with Whole-body vibration platform | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
D: Arm Label: New Flooring; Type: EXPERIMENTAL; Interventions: Other: New flooring | Arm Label: Standard Flooring; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New flooring; Assigned to Arm(s): New Flooring

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rationalisation of Polypharmacy in the Elderly by the RASP Instrument (Rationalisation of Home Medication by an Adjusted STOPP-list in Older Patients): a Prospective, Clinical Trial.
Brief Summary: The aim of this study is to determine whether a clinical pharmacist using the RASP list (RASP = Rationalisation of home medication by an adjusted STOPP-list in older patients; STOPP = Screening Tool of Older Persons' potentially inappropriate Prescriptions) can optimise the drug use in elderly inpatients.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention
B: Arm Label: Before collarborative pharmaceutical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: After collarborative pharmaceutical care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Pharmaceutical Care | Intervention Type: OTHER; Name: Collaborative Pharmaceutical Care; Assigned to Arm(s): After collarborative pharmaceutical care
C: Arm Label: RASP; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmaceutical care plan, mostly based on the RASP | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care plan, mostly based on the RASP; Assigned to Arm(s): RASP
D: Intervention Type: BEHAVIORAL; Name: Opinion leader generated and endorsed evidence summaries; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rationalisation of Polypharmacy in the Elderly by the RASP Instrument (Rationalisation of Home Medication by an Adjusted STOPP-list in Older Patients): a Prospective, Clinical Trial.
Brief Summary: The aim of this study is to determine whether a clinical pharmacist using the RASP list (RASP = Rationalisation of home medication by an adjusted STOPP-list in older patients; STOPP = Screening Tool of Older Persons' potentially inappropriate Prescriptions) can optimise the drug use in elderly inpatients.


Options:
A: Arm Label: RASP; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmaceutical care plan, mostly based on the RASP | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care plan, mostly based on the RASP; Assigned to Arm(s): RASP
B: Arm Label: Medication review; Type: EXPERIMENTAL; Interventions: Other: Medication review | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Medication review; Assigned to Arm(s): Medication review
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multidisciplinary treatment | Intervention Type: BEHAVIORAL; Name: multidisciplinary treatment; Assigned to Arm(s): Pharmacist intervention
D: Arm Label: Pharmaceutical care program; Type: EXPERIMENTAL; Interventions: Other: Pharmaceutical Care Program | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: Pharmaceutical Care Program; Assigned to Arm(s): Pharmaceutical care program | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in Children and Adolescents 1 to Less Than 18 Years With Type 1 Diabetes Mellitus on a Basal-bolus Regimen With Insulin Aspart as Bolus Insulin, Followed by a 26-week Extension Investigating Long Term Safety (BEGIN™: Young 1)
Brief Summary: This trial is conducted in Africa, Asia, Europe and the United States of America (USA).

The aim of this trial is to investigate the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus.


Options:
A: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Arm Label: NPH insulin; Type: EXPERIMENTAL; Interventions: Drug: insulin NPH, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): NPH insulin | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): NPH insulin, insulin detemir
B: Arm Label: Insulin Degludec + Insulin Aspart; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin aspart | Arm Label: Insulin Detemir +Insulin Aspart; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): Insulin Degludec + Insulin Aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): Insulin Detemir +Insulin Aspart | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): Insulin Degludec + Insulin Aspart, Insulin Detemir +Insulin Aspart
C: Arm Label: IDeg OD; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin aspart | Arm Label: IGlar OD; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IGlar OD | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDeg OD, IGlar OD
D: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation
Brief Summary: Background: In chronic obstructive pulmonary disease, the prognosis for patients who have survived an episode of acute hypercapnic respiratory failure due to an exacerbation is poor. Despite being shown to improve survival and quality-of-life in stable patients with chronic hypercapnic respiratory failure, long-term noninvasive ventilation is controversial in unstable patients with frequent exacerbations, complicated by acute hypercapnic respiratory failure. In an uncontrolled group of patients with previous episodes of acute hypercapnic respiratory failure, treated with noninvasive ventilation, we have been able to reduce mortality and the number of repeat respiratory failure and readmissions by continuing the acute noninvasive ventilatory therapy as a long-term therapy.

Methods: Multi-center open label randomized controlled trial of 150 patients having survived an admission with noninvasive ventilatory treatment of acute hypercapnic respiratory failure due chronic obstructive pulmonary disease. The included patients are randomized to usual care or to continuing the acute noninvasive ventilation as a long-term therapy, both with a one-year follow-up period.

End points: The primary endpoint is one-year mortality; secondary endpoints are time to death or repeat acute hypercapnic respiratory failure, number of readmissions and repeat acute hypercapnic respiratory failure, exacerbations, dyspnea, quality of life, sleep quality, lung function, and arterial gases.


Options:
A: Intervention Type: DEVICE; Name: Noninvasive positive pressure ventilation; Assigned to Arm(s): N/A
B: Arm Label: Long Term Oxygen Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non Invasive Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: Non Invasive Ventilation | Intervention Type: DEVICE; Name: Non Invasive Ventilation; Assigned to Arm(s): Non Invasive Ventilation
C: Arm Label: LTNIV group; Type: EXPERIMENTAL; Interventions: Device: LTNIV | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: LTNIV; Assigned to Arm(s): LTNIV group
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Single-Arm, Multi-Center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE)
Brief Summary: The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right ventricle (RV) to left ventricle (LV) diameter within 48 =/- 6 hours in participants with massive or submassive PE.


Options:
A: Arm Label: EkoSonic® Endovascular System; Type: EXPERIMENTAL; Interventions: Drug: recombinant tissue plasminogen activator, Device: EKOS EkoSonic Endovascular System | Intervention Type: DRUG; Name: recombinant tissue plasminogen activator; Assigned to Arm(s): EkoSonic® Endovascular System | Intervention Type: DEVICE; Name: EKOS EkoSonic Endovascular System; Assigned to Arm(s): EkoSonic® Endovascular System
B: Arm Label: Single Arm; Type: OTHER; Interventions: Device: Indigo Aspiration System | Intervention Type: DEVICE; Name: Indigo Aspiration System; Assigned to Arm(s): Single Arm
C: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin
D: Arm Label: pulmonary embolism; Type: N/A; Interventions: N/A

Answer: A